Drug intelligence / Profile preview

RMD1406

Development stage: Preclinical
Lead developer: Remedium Bio
Modality: Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous

Overview

RMD1406 is an investigational gene therapy candidate being developed by Remedium Bio (formerly Remedium Technologies) for the treatment of metabolic disorders. The program utilizes Remedium's proprietary delivery platforms, which include the 'Minerva' lipid nanoparticle (LNP) system for non-viral delivery and the 'Prometheus' AAV-based platform. RMD1406 is designed to facilitate the endogenous production of therapeutic proteins to regulate metabolic pathways. While the specific molecular target of RMD1406 has not been publicly disclosed, it is part of a broader metabolic portfolio that includes assets targeting GLP-1 and GIP. As of 2024, RMD1406 is in the preclinical stage of development.

Beyond the preview

Go deeper on RMD1406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMD1406.

Explore the full profile